Gaucher, FR

Antoine Gaucher, Andrezieux Boutheon FR

Patent application number	Description	Published
20090062695	APPARATUS FOR MEASURING AND ANALYZING EFFORTS EXERTED BY THE LEGS - The invention concerns methods and apparatus for measuring and analyzing leg effort. The apparatus includes a motorized treadmill secured to two superimposed upper and lower assemblies that are mounted in combination with measurement sensors. The apparatus may be used for analyzing the forces exerted while running, for example, by means of the lower assembly, or walking, by means of both the lower and upper assemblies.	03-05-2009

Bérangère Gaucher, Mulhouse FR

Patent application number	Description	Published
20100056478	Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors - A pharmaceutically composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).	03-04-2010
20120040957	Novel Bicyclic Antibiotics - Compounds of formula (I) wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; R1 and R2, independently of one another, represent hydrogen or a substituent selected from hydroxy, halogen, carboxy, amino, C1-C6alkylamino, di(C1-C6alkyl)amino, mercapto, cyano, nitro, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylthio, C1-C6alkylamino-carbonyloxy, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkylcarbonyloxy, C1-C6alkyl-sulfonyloxy, C1-C6heteroalkylcarbonyloxy, C5-C6heterocyclyl-carbonyloxy, C1-C6heteroalkyl, C1-C6heteroalkoxy, wherein heteroalkyl, heteroalkoxy groups or heterocyclyl comprise 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, in which substituents the alkyl moieties are unsubstituted or further substituted by halogeno, cyano, hydroxy, C1-C4alkoxy, C1-C4alkylcarbonyl, C1-C4alkoxycarbonyl, unsubstituted or substituted phenoxy or phenylcarbonyl, unsubstituted or substituted C5-C6heterocyclyl or carboxy; A1 represents a divalent group of one of the formulae —O—(CH	02-16-2012
20140221348	NOVEL BICYCLIC ANTIBIOTICS - The antibacterial compound of formula I	08-07-2014
20140235855	Tricyclic Antibiotics - Compounds of formula (I), wherein A1 represents —O—, —S— or —CH	08-21-2014
20150031662	USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS - A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).	01-29-2015
20150080373	NOVEL BICYCLIC ANTIBIOTICS - The antibacterial compound of formula I	03-19-2015

Bérangère Gaucher, Mulhouse FR

Patent application number	Description	Published
20100056478	Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors - A pharmaceutically composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).	03-04-2010
20120245345	TRICYCLIC ANTIBIOTICS - Compound of formula (I): wherein A1 represents —O—, —S— or —N—R3; A2 represents —CH	09-27-2012

Christine Gaucher, Sequeden FR

Patent application number	Description	Published
20090175789	Antibody raised against the ldl receptor - The present invention relates to a monoclonal antibody raised against the human LDL (Low Density Lipoprotein) receptor, binding to the peptide corresponding to amino acids 195-222 (SEQ ID NO: 1) in the peptide sequence for the human LDL receptor; to the use thereof as a drug; to a pharmaceutical composition containing this antibody; and to the use thereof in immunohistochemical analyses of cancerous, healthy, or cirrhotic tissues, in Western-Blot or ELISA analyses, or in in vivo quantification tests.	07-09-2009

Christine Gaucher, Sequedin FR

Patent application number	Description	Published
20090053233	Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations - The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of FcγRIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma.	02-26-2009
20090081216	TREATMENT OF PATHOLOGIES WHICH ESCAPE THE IMMUNE RESPONSE, USING OPTIMIZED ANTIBODIES - The invention relates to the use of potimised human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies having a strong affvinity for receptor CD16 of the effector cells of the immune system and being able to induce the secretion of cytokines and interleukins, in particular 1“IFN? Or 1” IL2, for the treatment of pathologies for which the target cells only express a low antigenic density and in which the effector cells can only be recruited in small quantities.	03-26-2009
20090130094	Cytotoxic Antibodies Directed Against Antibodies Inhibiting Factor VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.	05-21-2009
20100303826	Use of ADCC-Optimized antibodies for treating weak patients - The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.	12-02-2010
20100323368	Cytokine production-inducing antibody - The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.	12-23-2010
20110274684	CYTOTOXIC ANTIBODIES DIRECTED AGAINST ANTIBODIES INHIBITING FACTOR VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.	11-10-2011
20110311556	ANTI-RHESUS D MONOCLONAL ANTIBODY - The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4.	12-22-2011
20140017243	USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS - The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.	01-16-2014

Didier Gaucher, Cretell Cedex FR

Patent application number	Description	Published
20110254288	CONTROL DEVICE COMPRISING A SWITCH, CONTROL DEVICE HOUSING, AND SWITCH FOR A CONTROL DEVICE - The invention relates to a control device for the door leaf a transport vehicle, comprising a housing (	10-20-2011

Fabien Gaucher, Lyon FR

Patent application number	Description	Published
20130338455	DEVICE FOR MONITORING A MEDICAL PROSTHESIS AND THE HUMAN BODY - A device for monitoring a medical prosthesis and the human body includes a sensor for generating signals depending on surrounding stresses, a processor for processing the signals emitted by the sensor in order to convert the signals into data, a storage device for storing the data, a device for wireless transmission of the stored data, and a supply of electrical energy. The device is included in at least one casing, which is made of biocompatible material and has a device for fixing to a bone.	12-19-2013